AstraZeneca's Seroquel XR launched in USA
Anglo-Swedish drug major AstraZeneca has launched its once-daily Seroquel XR (quetiapine fumarate) extended-release tablets in the USA for the acute treatment of the depressive episodes associated with bipolar disorder and the manic and mixed episodes associated with bipolar I disorder, as well as the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex.
The agent is also now available in two new tablet strengths, 50mg and 150mg. Once-daily Seroquel XR is the only US-approved medication for the treatment of acute depressive, manic and mixed episodes of bipolar disorder.
Approximately eight million American adults may be affected by bipolar disorder, also known as manic-depressive illness, a serious psychiatric condition characterized by recurring episodes of depression and mania. For many patients with bipolar disorder, the depressive symptoms are more disruptive than the manic symptoms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze